Baseline variables predictive of remission at 24 months in the Combination of Anti-Rheumatic Drugs in Early RA (CARDERA) clinical trial using univariate and multivariate logistic regression.
| Univariate | Multivariate | ||||
|---|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | Coefficient (β) | |
| Age | 0.98 (0.96, 1.00) | 0.049 | 0.97 (0.95, 0.99) | 0.014 | –0.03 |
| Male | 2.91 (1.75, 4.85) | < 0.001 | 3.14 (1.80, 5.46) | < 0.001 | 1.1 |
| Rheumatoid factor | 0.96 (0.57, 1.62) | 0.884 | — | — | — |
| Nodules | 0.64 (0.34, 1.24) | 0.186 | — | — | — |
| Health Assessment Questionnaire | 0.67 (0.47, 0.96) | 0.027 | 1.07 (0.66, 1.72) | 0.79 | — |
| Larsen score | 0.98 (0.96, 1.00) | 0.057 | — | — | — |
| Tender joint count | 0.93 (0.90, 0.97) | < 0.001 | 0.94 (0.90, 0.98) | 0.006 | –0.06 |
| Swollen joint count | 0.95 (0.91, 1.00) | 0.03 | 1.00 (0.93, 1.05) | 0.89 | — |
| Erythrocyte sedimentation rate | 0.99 (0.98, 1.00) | 0.144 | — | — | — |
| Patient global assessment | 0.99 (0.98, 1.00) | 0.041 | 0.99 (0.98, 1.00) | 0.23 | — |
| SF-36 MCS | 1.02 (1.00, 1.03) | 0.081 | |||
| SF-36 PCS | 1.02 (1.00, 1.05) | 0.097 | |||
SF-36 MCS: Medical Outcomes Study Short-Form 36 mental component score; PCS: physical component score.